https://www.live-feeds.com/feed/moderna-ceo-s-realistic-approach-to-innovationContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/moderna-ceo-s-realistic-approach-to-innovationhttps://www.live-feeds.com/feed/moderna-ceo-s-realistic-approach-to-innovation#u85993Sun, 27 Sep 2026 07:10:56 +0000Moderna stock surged 9 percent to hit a new high, positioning the company as September's number two S&P 500 stock. The rally follows a realistic innovation approach from the chief executive, emphasizing that the company extends beyond Covid vaccines. Bolstering this market momentum, the first personalized mRNA cancer vaccine passed a major test. Phase 3 melanoma data secured a presidential symposium slot, drawing alongside market moves from partners like Merck and competitor BioNTech.Why it mattersModerna has relied heavily on its Covid-19 vaccine revenue since the pandemic, making pi